Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS1501
- Development stage
- Phase 2
- Lead developer
- Zhongke Aishen Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
AS1501 is an investigational macromolecular drug developed for the treatment of liver damage and liver failure, including those caused by viral, autoimmune, and drug-induced hepatitis. It acts as a TRAIL (TNF-related apoptosis-inducing ligand) inhibitor by binding to TRAIL and preventing its interaction with Death Receptor 5 (DR5) on cell membranes. This mechanism blocks cell apoptosis triggered by the TRAIL-DR5 pathway, thereby protecting against organ damage mediated by excessive host immune response. The drug is being developed primarily for acute-on-chronic liver failure (ACLF), with additional potential in other conditions involving pathological apoptosis such as myocardial infarction, cerebral stroke, and possibly Alzheimer's disease. Clinical development has reached Phase 2 in China[1][2][3][4][5].
- Brand names
- AS1501AS-1501AS 1501
- Other names
- 注射用AS1501
02
Targets
TNFSF10 (Tumour necrosis factor-related apoptosis-inducing ligand)TNFRSF10B (DR5)
Beyond the preview
Go deeper on AS1501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS1501.